Outcomes after standard chemotherapy or epigenetic therapy
| . | Chemotherapy . | Epigenetic therapy . | P . |
|---|---|---|---|
| Total patients, n (%) | 557 (83%) | 114 (17%) | |
| Outcome, n (%) | |||
| ORR | 263 (47%) | 33 (29%) | < .001 |
| CR | 235 (42%) | 32 (28%) | .005 |
| CRp | 28 (5%) | 1 (1%) | NR |
| No response | 189 (34%) | 63 (55%) | NR |
| ED < 8 wk | 102 (18%) | 13 (11%) | .075 |
| Median OS, mo | 6.7 | 6.5 | .413 |
| 1-y | 34% | 31% | |
| 2-y | 18% | 11% | |
| Median RFS, mo | 12.0 | 10.5 | .843 |
| 1-y | 50% | 45% | |
| 2-y | 30% | 40% | |
| . | Chemotherapy . | Epigenetic therapy . | P . |
|---|---|---|---|
| Total patients, n (%) | 557 (83%) | 114 (17%) | |
| Outcome, n (%) | |||
| ORR | 263 (47%) | 33 (29%) | < .001 |
| CR | 235 (42%) | 32 (28%) | .005 |
| CRp | 28 (5%) | 1 (1%) | NR |
| No response | 189 (34%) | 63 (55%) | NR |
| ED < 8 wk | 102 (18%) | 13 (11%) | .075 |
| Median OS, mo | 6.7 | 6.5 | .413 |
| 1-y | 34% | 31% | |
| 2-y | 18% | 11% | |
| Median RFS, mo | 12.0 | 10.5 | .843 |
| 1-y | 50% | 45% | |
| 2-y | 30% | 40% | |
CRp indicates CR with incomplete platelet recovery; ED, early death; RFS, relapse-free survival; and NR, not reported.